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Collagenase ointment and topical timolol gel
for treating idiopathic pyoderma
gangrenosum
To the Editor:A 77-year-oldwomanwas admitted to a
university hospital for evaluation and treatment of a
painful and rapidly growing 7.5-3 9-cm ulcer on her
right medial ankle. Physical examination showed
ulceration with central granulation tissue and
surrounding violaceous rim (Fig 1, A). Biopsy
demonstrated dermal neutrophilic inflammation
with edematous undermining of the epidermis. Fite,
Grocott methenamine silver, and Brown-Brenn
stains by histochemistry were negative for infectious
mycobacteria, fungi, and routine bacteria. Pyoderma
gangrenosum (PG) was established as the diagnosis.bowel disease. B, SGP ulcerations on the head
ulceration was triggered by the following procedu
right jaw pain and difficulty chewing in October
repair the right temple defect; incision and draina
were noted for a 2-fold elevation in erythrocyte se
evidence of myeloproliferative disease, hepatitis
vasculitides. The patient never experienced gastr
bleeding and did not undergo a colonoscopy. C
features: plasma cells, histiocytes, sinus track epit
evidence of polarizable foreign material and per
were negative. D, Healed SGP with residual sc
intravenous infliximab and topical calcineurin inh
Open access under CC BY-NC-ND license.Past medical history was noncontributory. Workup
was negative for underlying malignancy, inflamma-
tory bowel disease, and other autoimmune
processes. After intralesional steroid injection
(Kenalog 5 mg/mL, 1 mL total volume), the patient
was discharged with a 2-week oral prednisone taper
and a topical regimen consisting of clobetasol
ointment with topically applied crushed dapsone
under occlusive Biatain absorbent polyurethane
foam dressings. For the first month the lesion
responded well, and by day 33 the ulcer had
decreased to 6 3 6 cm. At this time, the patient was
given a second intralesional steroid injection
and was started on timolol maleate 0.5%
gel applied topically to the entire border of the ulcer
daily while continuing both topical clobetasol and
dapsone.
However, progress ceased during the second
month and on day 61 the ulcer was still 6 3 6 cm
(Fig 1, B). The patient wished to discontinue
topical dapsone due to discomfort and declined
systemic medications. We prescribed daily
topical collagenase 250 U/g ointment (Santyl) to
the entire ulcer bed, in addition to continued daily
topical timolol gel. Over the next 30 days, the wound
became more shallow and steadily decreased in size
from 36 cm2 to 10 cm2. After 36 more days of topical
collagenase and timolol gel under occlusion, the
ulcer was completely reepithelialized (Fig 1, C ).
There are currently no specific or uniformly
effective therapies for PG; most are directed at
reducing inflammation. One alternative approach
focuses on enhancing keratinocyte migration to
speed reepithelialization. Keratinocytes express
beta2-adrenergic receptors, and can also produce
beta-adrenergic receptor agonists that decrease
keratinocyte migration.1 Topical beta2-adrenergic
receptor antagonists such as timolol have shown
efficacy in treating chronic venous leg ulcers2 andother
recalcitrantwounds.3,4 Topical timolol gel is alsowidely
used in ulcerated infantile hemangiomas.5 Of note,
our patient used the timolol gel and not the solution., neck, and chest before treatment. Each
res: right temporal artery biopsy to evaluate
2009; attempted graft from the right neck to
ge of a cyst on the chest. Laboratory studies
dimentation rate, but otherwise there was no
, or antineutrophil cytoplasmic antibody
ointestinal symptoms such as pain or rectal
, Histopathology of SGP demonstrating 4
helial lining, and neutrophils. There was no
iodic acidSchiff and acid fast bacilli stains
ar formation on the head and neck after
ibitor therapy.
Fig 1. A, Day 0. B, Day 61. C, Day 127.
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e226 LettersImproving removal of necrotic tissue and
exuberant granulation could present another
alternative approach to enhance wound healing. In
PG, manual debridement is contraindicated due to
pathergy risk. Collagenase ointment contains the
metalloproteinases collagenase I and collagenase II,
andmay alsohaveother anti-inflammatoryproperties.
It has been shown to improve outcomes in burns
and chronic wounds. To our knowledge, use of
enzymatic debridement has not been previously
reported in PG.
In light of the negative side effects of chronic
systemic steroid use and the frequently recalcitrant
nature of PG, daily topical timolol gel applied to the
ulcer border and collagenase ointment applied to the
ulcer base may present a useful alternative for
treatment of chronic idiopathic PG.
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